空间生物学科研试剂研发商Haga Bioscience筹集230万美元种子轮融资，旨在连接空间生物标志物发现与临床转化-动脉网

Haga Bioscience raises $2.3m in oversubscribed seed round to bridge spatial biomarker discovery and clinical translation

D-Pharm 等信源发布 2026-06-05 13:18



可切换为仅中文







Haga Bioscience (HAGA.BIO), a Swedish spatial biology startup, announced it has closed a SEK 20.9 million (approximately USD 2.3 million) oversubscribed

瑞典空间生物学初创公司 Haga Bioscience（HAGA.BIO）宣布完成一轮超额认购的融资，金额为 2090 万瑞典克朗（约合 230 万美元）。

seed financing

种子轮融资

round bringing total funding, including pre-seed financing, to approximately USD 3 million. The company will use the capital to initiate commercialization of its spatial biology technologies designed specifically for validation and translational workflows.

本轮融资使包括预种子轮融资在内的总融资额达到约300万美元。公司将利用这笔资金启动其专为验证和转化工作流程设计的空间生物学技术的商业化进程。

The financing included participation from Almi Invest, Life Science Invest, and SU Ventures, alongside undisclosed life science industry veterans, family offices, and private investors.

本轮融资由Almi Invest、Life Science Invest和SU Ventures领投，另有未具名的生命科学行业资深人士、家族办公室及私人投资者参与。

Founded in 2024, Stockholm-based HAGA.BIO is focused on advancing the next phase of spatial biology by bridging the gap between spatial RNA biomarker discovery and clinical translation. While recent advances in spatial biology have enabled the discovery of large numbers of novel tissue based RNA biomarkers, validating these findings across large clinical cohorts remains a major challenge due to sample throughput and the high costs.

HAGA.BIO 于2024年成立，总部位于斯德哥尔摩，致力于通过弥合空间RNA生物标志物发现与临床转化之间的差距，推动空间生物学进入下一阶段。尽管空间生物学的最新进展使得大量新型组织RNA生物标志物的发现成为可能，但由于样本通量限制和高昂成本，在大型临床队列中验证这些发现仍然是一项重大挑战。

HAGA.BIO said its technologies are specifically designed to enable cost effective scalable validation and translational workflows..

HAGA.BIO 表示，其技术专为实现具有成本效益、可扩展的验证及转化工作流程而设计。

COVID-19 : Measuring viral RNA to predict which patients will die

COVID-19：通过测量病毒RNA预测哪些患者会死亡

A statistical model uses a blood biomarker of SARS-CoV-2 to identify infected patients who are most at risk of dying of COVID-19

一种统计模型利用SARS-CoV-2的血液生物标志物来识别最有可能死于COVID-19的感染患者

Read news

阅读新闻

The technologies enable sensitive, specific detection of single nucleotide variants (SNVs) on RNA directly in situ, and are built on next-generation in situ hybridization methods developed by co-founders Hower Lee (CEO), Marco Grillo (CSO), and Mats Nilsson, professor at Stockholm University and scientific co-founder of the company..

这些技术能够实现高灵敏度、高特异性的原位单核苷酸变异（SNV）检测，直接针对RNA进行。该技术基于由联合创始人Hower Lee（首席执行官）、Marco Grillo（首席科学官）以及斯德哥尔摩大学教授兼公司科学联合创始人Mats Nilsson开发的新一代原位杂交方法构建而成。

Additional co-founders include Malte Kuhnemund, Daniel Gyllborg, and Xiaoyan Qian, previously at 10x Genomics. Kuhnemund and Qian co-founded Cartana in 2017, a SciLifeLab spinout whose in situ RNA sequencing technology was acquired by 10x Genomics in 2020 and integrated into the Xenium platform.

其他联合创始人包括此前任职于10x Genomics的Malte Kuhnemund、Daniel Gyllborg和钱晓燕。Kuhnemund与钱晓燕于2017年联合创立了Cartana，这是一家源自SciLifeLab的衍生公司，其原位RNA测序技术于2020年被10x Genomics收购，并整合至Xenium平台中。

“Until now, the field has lacked robust in situ variant calling on FFPE tissue samples with high sensitivity and specificity,” said Hower Lee, co-founder and CEO of Haga Bioscience. “Addressing this challenge enables new possibilities for translational research.”

“迄今为止，该领域缺乏在福尔马林固定石蜡包埋（FFPE）组织样本上进行高灵敏度和高特异性的稳健原位变异检测，”Haga Bioscience 联合创始人兼首席执行官 Hower Lee 表示。“解决这一挑战为转化研究开辟了新的可能性。”

“Discovery is no longer the bottleneck,” said Mats Nilsson, professor at Stockholm University and scientific co-founder of Haga Bioscience. “The next major step for the field is translating and validating these discoveries at scale and ultimately into clinical use. That is precisely what HAGA.BIO aims to enable.”.

“发现已不再是瓶颈，”斯德哥尔摩大学教授、Haga Bioscience科学联合创始人马茨·尼尔松表示。“该领域的下一个重大步骤是在大规模上转化并验证这些发现，并最终将其应用于临床。这正是HAGA.BIO旨在实现的目标。”

The financing supports product development, commercialization, and collaborations with academic and industry partners to advance translational spatial biology. The company officially announced the early access program at the Cancer Research UK Cambridge Institute In Situ Hybridisation and Spatial Omics Symposium on May 20, 2026. .

该融资支持产品开发、商业化以及与学术界和行业伙伴的合作，以推动转化空间生物学的发展。该公司于2026年5月20日在英国癌症研究会剑桥研究所举办的原位杂交与空间组学研讨会上正式宣布了早期访问计划。

Through the program, HAGA.BIO is providing early access to HAGA Pattern™, a multiplexed spatial gene expression assay, and HAGA Point™, a spatial assay for in situ SNV detection on RNA.

通过该计划，HAGA.BIO 正在提供对 HAGA Pattern™（一种多重空间基因表达检测技术）和 HAGA Point™（一种用于 RNA 原位单核苷酸变异检测的空间检测技术）的早期访问权限。

HAGA.BIO will also participate in the 2026 European Association for Cancer Research (EACR) Congress in Budapest from June 8 to 11, 2026, where the company plans to present its latest advances in translational spatial RNA analysis.

HAGA.BIO 还将参加于2026年6月8日至11日在布达佩斯举行的2026年欧洲癌症研究协会（EACR）大会，届时该公司计划展示其在转化空间RNA分析领域的最新进展。

https://www.bionity.com/en/news/1188849/haga-bioscience-raises-2-3m-in-oversubscribed-seed-round-to-bridge-spatial-biomarker-discovery-and-clinical-translation.html

Sixfold Bioscience completes $10.5M USD seed financing

Sixfold Bioscience 完成 1050 万美元种子轮融资

Funding will support the advancement of Sixfold’s Mergo RNA therapeutics delivery platform, enabling delivery of mRNA and siRNA to tissues beyond the liver

资金将支持Sixfold公司Mergo RNA治疗递送平台的进步，实现mRNA和siRNA向肝脏以外组织的递送。

Read news

阅读新闻